Job Trends
Labor Market Reports
The life sciences job market continues to shift. BioSpace’s Q2 2025 U.S. Life Sciences Job Market Report is now available, offering exclusive insights into the latest hiring trends, layoffs, and workforce dynamics across the life sciences industry.
Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
Now Hiring
Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Career Advice
There are a few lessons from the pandemic about the work which everyone should learn to be more productive. We have compiled the list of them. So let’s take a look.
THE LATEST
There was plenty of clinical trial updates last week. Here’s a look.
Viatris executive chairman Robert Coury said that seeking new stewards for the site is the best route to ensure that people will have jobs and that the property would remain useful.
Moderna will construct a manufacturing facility in Canada to provide direct access to mRNA vaccines for the COVID-19 pandemic and future viral threats and respiratory viruses.
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
Pfizer has made a deal with the small Locust Valley, New York-based company to manufacture and market the drug.
AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here’s more about it.
Mission Therapeutics and AbbVie announced their DUB inhibitor collaboration back in 2018.
Sierra will have access to AZD5153, a potent and selective BRD4 BET inhibitor, to initiate a study that combines the said component with momelotinib for treating patients with myelofibrosis.
A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.
Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.